GlycoMimetics, GLYC is showing recent insider trading activity. Public SEC records indicate that Invus Public Equities, Lp recently Bought $170,000 worth of shares on 2 weeks ago. With that said, our editors here at politicsandwallstreet.com, are adding GLYC to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of GLYC that Sold $8.6M worth of shares in the last 3 months, the Insider Confidence level of GlycoMimetics is trending Down.
Since these insiders have unique insights into what's happening at GlycoMimetics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for GLYC:
In addition, TradingView issued a Strong Sell rating for GLYC over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on GlycoMimetics, GLYC but please do your own research.
GLYC Summary: GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to GLYC, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of GLYC that Sold $8.6M worth of shares in the last 3 months, the Insider Confidence level of GlycoMimetics is trending Down.
Since these insiders have unique insights into what's happening at GlycoMimetics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for GLYC:
- Invus Public Equities, Lp - >10% Owner, Bought $170,000 worth of shares on 1 week ago
- Invus Public Equities, Lp - >10% Owner, Bought $711,000 worth of shares on 2 weeks ago
- Invus Public Equities, Lp - >10% Owner, Bought $3,019,647 worth of shares on 3 weeks ago
- Invus Public Equities, Lp - >10% Owner, Bought $37,101 worth of shares on 3 weeks ago
In addition, TradingView issued a Strong Sell rating for GLYC over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook.
Here is a bit more on GlycoMimetics, GLYC but please do your own research.
GLYC Summary: GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
- Recent Last Price: $1.33
- Price Change: -$0.14, -9.52%
- Yearly Gain: 33.64%
- Market Cap: $76.54M
- P/E Ratio: -1.426
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to GLYC, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================